Hepatitis B
Coverage of Hepatitis B in the Nexus archive.
- Doctors blast Trump for doubling down on vaccine policy modeled after Denmark
The American Medical Association criticized President Trump's executive order to align US childhood vaccine recommendations with Denmark's, which would reduce recommended immunizations from 17 to 11. The AMA stated the current vaccine schedule is based on decades of research and US-specific disease data.
- Experimental hepatitis B drug may offer ‘functional cure’ for some patients
An experimental hepatitis B drug called bepirovirsen may offer a 'functional cure' for some patients, with 20% of trial participants maintaining undetectable virus levels after stopping treatment. Developed by GSK and Ionis Pharmaceuticals, the drug is under fast-track FDA review and shows potential to address chronic hepatitis B, which affects over 250 million people globally.
- STAT+: Ahead of ASCO, all eyes on pancreatic cancer
Scientists report early progress in engineered heart patches and GSK announces a functional cure for hepatitis B. The article also highlights potential drug launches tied to President Trump's 'most-favored nation' claims and previews the upcoming ASCO meeting in Chicago.
- The latest developments on Ebola, hepatitis B, long Covid
The article promotes STAT’s free daily health newsletter 'Morning Rounds,' highlighting topics like Ebola, hepatitis B, and long Covid. It includes a call to sign up and mentions the author’s personal reading distractions.
- STAT+: Experimental hepatitis B treatment was a ‘functional cure’ for nearly 1 in 5, new data show
An experimental hepatitis B treatment, GSK’s bepirovirsen, achieved functional cures in 20% and 19% of patients in Phase 3 trials, significantly outperforming current treatments that achieve 1-3% success rates. The drug showed no functional cures in placebo groups, offering hope for a more effective solution to a disease affecting 250-300 million people globally.
- Genome editing can be risky. Meet the epigenome editors
Genome editing is highlighted as a risky technology, but a new approach called epigenome editing is introduced as a potential solution. The technology aims to address diseases such as atherosclerosis and hepatitis B.
- Senate hearings with RFK Jr. put Cassidy’s competing loyalties to Trump and science on display
Bill Cassidy, a Louisiana Republican senator and doctor, faces a dilemma as he questions Health Secretary Robert F. Kennedy Jr. in Senate hearings, balancing his loyalty to President Trump with his advocacy for vaccines. Kennedy's controversial anti-vaccine policies and recent shifts in public health messaging could impact Cassidy's reelection bid and congressional oversight of health programs.